# US 2017/0319577 A1 · Combinations of opioid/tlr4 antagonist and acetyl-para-aminophenol (apap) for use in the reduction of toll-like receptor 4(tlr4) and cyclooxygenase-2 (cox-2) activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319577 A1
- Document ID: US20170319577A1
- Status: Published application
- Kind: A1
- Application number: 15/651,926
- Filed: 2017-07-17
- Published: 2017-11-09
- Earliest claimed: 2013-03-15
- Assignees: Allodynic Therapeutics, LLC
- Applicants: Allodynic Therapeutics, Inc.
- Inventors: Annette Channa Toledano
- Web page: https://patentgrep.com/patent/US20170319577A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions for the treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is acetyl-para-aminophenol (APAP) that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic and nociceptive pain.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A method of reducing toll-like receptor 4 (TLR4) activity and of cyclooxygenase (COX-2) activity in a mammal by administering to the mammal an effective amount of naltrexone and acetyl-para-aminophenol (APAP).

### Claim 18 (depends on 17)

The method of claim 17, wherein the method is performed in a mammal who has activated TLR4.

### Claim 19 (depends on 18)

The method of claim 18, wherein the activation of TLR4 results in activation of a pro-inflammatory cascade.

### Claim 20 (depends on 19)

The method of claim 19, wherein simultaneous inhibition of TLR4 and COX-2 activation results in reduction of the pro-inflammatory cascade.
